ASA

EQS-News: Fiven ASA publishes Annual Report for 2023

Retrieved on: 
Wednesday, April 10, 2024
Annual report, PDF, RNS, London Stock Exchange, News, ASA, Security (finance)

Fiven has today published its annual report for 2023.

Key Points: 
  • Fiven has today published its annual report for 2023.
  • The report is attached to this press release and is available on Fiven's website .
  • Please use the link below to read the full Annual Report as PDF:
    This information is information that Fiven ASA is obliged to make public pursuant to the EU Market Abuse Regulation.
  • RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

poLight ASA Confirms Design Win with Vuzix Shield Industrial AR Smart Glasses

Retrieved on: 
Monday, April 8, 2024
Wearables, Mobile Technology, Mobile, Wireless, Technology, Engineering, Photography, Manufacturing, Audio, Video, Hardware, Consumer Electronics, Artificial Intelligence, Augmented reality, RGB, Smartglasses, 3D, AI, Workflow, ASA, Workforce, PLT, Multimedia, Camera

poLight ASA (OSE: PLT) today confirms that Vuzix Shield ™ AR smart glasses have been released for general availability in the industrial enterprise market.

Key Points: 
  • poLight ASA (OSE: PLT) today confirms that Vuzix Shield ™ AR smart glasses have been released for general availability in the industrial enterprise market.
  • Besides being the world’s first binocular waveguide smart glasses implemented for industrial use, Vuzix Shield also uses TLens® in its two front-facing stereo RGB autofocus cameras.
  • View the full release here: https://www.businesswire.com/news/home/20240408284501/en/
    Vuzix Shield™ AR glasses, the world’s first binocular waveguide smart glasses implemented for industrial use, utilizes poLight ASA TLens® in its two front-facing stereo RGB autofocus cameras.
  • “Vuzix is a veteran in the industrial, enterprise AR market, and the Vuzix Shield product boasts state-of-the-art stereo AF cameras leveraging our TLens® technology.

American Student Assistance Announces Intention to Invest $25 Million in Funds, Early-Stage Firms, and Companies with Diverse Management Focused on Increasing Equitable Access to Impactful Career Readiness and Future of Work Opportunities for Young People

Retrieved on: 
Monday, April 8, 2024
Innovation, Entrepreneurship, Impact investing, Tablet, Suite, Investment, ASA, Creativity

Since launching its investment strategy in April of 2022, ASA has invested over $40 million in key sectors, such as postsecondary pathways, workforce development, and career-focused education.

Key Points: 
  • Since launching its investment strategy in April of 2022, ASA has invested over $40 million in key sectors, such as postsecondary pathways, workforce development, and career-focused education.
  • As a result, more than 40 million learners have been impacted through fund investments, as well as through direct investments.
  • "At ASA, we believe that increasing diversity in, and access to, early-stage capital is integral to driving innovation and creativity.
  • The new initiative will also invest in diverse managers of funds that are mission-aligned to ASA's goals.

AvAir and Finnair Build on Collaboration

Retrieved on: 
Monday, April 8, 2024
A350, A330, ISO 9001, Partnership, Oropharyngeal airway, A319, ASA, A321, A320, Airline

CHANDLER, Ariz., April 8, 2024 /PRNewswire/ -- AvAir, an industry-leading inventory solutions provider for the aviation aftermarket and Finnair are pleased to announce that AvAir has acquired more than half a million parts from Finnair with more than 14,000 line items.

Key Points: 
  • CHANDLER, Ariz., April 8, 2024 /PRNewswire/ -- AvAir , an industry-leading inventory solutions provider for the aviation aftermarket and Finnair are pleased to announce that AvAir has acquired more than half a million parts from Finnair with more than 14,000 line items.
  • Finnair has worked with AvAir for more than 15 years, transacting more than 20,000 line items, historically.
  • "Partnering with Finnair and propelling our relationship forward is a win-win allowing AvAir to expand its offerings and be solutions-oriented for our customers while providing an outlet for Finnair's assets," said Zach Hall, vice president of business development at AvAir.
  • With more than 26 million in-stock components, AvAir offers solutions for customers and suppliers to buy, sell, exchange, loan, lease, or manage assets and inventories.

AvAir and Finnair Build on Collaboration

Retrieved on: 
Monday, April 8, 2024
A350, A330, ISO 9001, Partnership, Oropharyngeal airway, A319, ASA, A321, A320, Airline

CHANDLER, Ariz., April 8, 2024 /PRNewswire/ -- AvAir, an industry-leading inventory solutions provider for the aviation aftermarket and Finnair are pleased to announce that AvAir has acquired more than half a million parts from Finnair with more than 14,000 line items.

Key Points: 
  • CHANDLER, Ariz., April 8, 2024 /PRNewswire/ -- AvAir , an industry-leading inventory solutions provider for the aviation aftermarket and Finnair are pleased to announce that AvAir has acquired more than half a million parts from Finnair with more than 14,000 line items.
  • Finnair has worked with AvAir for more than 15 years, transacting more than 20,000 line items, historically.
  • "Partnering with Finnair and propelling our relationship forward is a win-win allowing AvAir to expand its offerings and be solutions-oriented for our customers while providing an outlet for Finnair's assets," said Zach Hall, vice president of business development at AvAir.
  • With more than 26 million in-stock components, AvAir offers solutions for customers and suppliers to buy, sell, exchange, loan, lease, or manage assets and inventories.

BlueNord: Preliminary Production for March and First Quarter 2024

Retrieved on: 
Monday, April 8, 2024
Disclosure, ASA, Security (finance)

OSLO, Norway, April 8, 2024 /PRNewswire/ -- BlueNord ASA ("BlueNord" or the "Company") has today announced its preliminary production figures for March and first quarter 2024.

Key Points: 
  • OSLO, Norway, April 8, 2024 /PRNewswire/ -- BlueNord ASA ("BlueNord" or the "Company") has today announced its preliminary production figures for March and first quarter 2024.
  • The Company had a preliminary production in March of net 24.0 mboepd and BlueNord exited the month with a production rate of 27.0 mboepd as the Halfdan NE well HBA-27B came online.
  • The preliminary first quarter 2024 production figure was 23.5 mboepd, above the quarterly guidance of 22.0 - 23.0 mboepd.
  • This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and requirements under the EU Market Abuse Regulation.

AMERICAN SKIN ASSOCIATION SPRING GALA CELEBRATES OUTSTANDING HONOREES

Retrieved on: 
Friday, April 5, 2024
Eli Lilly, Organization, Master of ceremonies, Psoriasis, Vitiligo, Atopic dermatitis, Skin cancer, NBC, Patient, Research, Pioneer, Hope, Doctor of Philosophy, MD, Student, Inauguration, SPOTS, ASA, Skin, Melanoma, Eli Lilly and Company, Plaza Hotel, Physician, Pharmaceutical industry

NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala. They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health. The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.

Key Points: 
  • Gala honors Pioneer in Dermatology, Emma Guttman-Yassky, MD, PhD and Global Pharmaceutical Leader Eli Lilly and Company
    NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala.
  • They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health.
  • The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.
  • Recipients, who work on breakthrough efforts to prevent, detect, and treat skin cancer and other skin diseases, have gone on to become top researchers in dermatology.

Equinor presents 2023 Integrated annual report

Retrieved on: 
Thursday, March 21, 2024
Annual report, Lindworm, Tax, Growth, Exchange, Snorre, Anders Opedal, GHG, Global warming potential, Gullfaks oil field, History, Acquisition, Security (finance), CCS, Nature, Carbon, Disclosure, Bank statement, Accident, Publication, CO2, Kilowatt-hour, Energy, ASA, Gina Krog, Use, Baugé, USD, NCS, Fatality, EQNR, Renewable energy

Equinor ASA (OSE: EQNR, NYSE: EQNR) publishes 2023 Integrated annual report, combining financial and sustainability reporting.

Key Points: 
  • Equinor ASA (OSE: EQNR, NYSE: EQNR) publishes 2023 Integrated annual report, combining financial and sustainability reporting.
  • The report for 2023 integrates the annual financial and sustainability reporting, reflecting the importance of sustainability for Equinor’s operational and financial performance, to our people, investors and other stakeholders.
  • The Equinor 2023 Annual Report on Form 20-F may be downloaded from Equinor's website at www.equinor.com.
  • See Use and reconciliation of non-GAAP financial measures in the integrated annual report for more details.

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Retrieved on: 
Thursday, March 21, 2024
Head, Survival, Immunotherapy, Cervical cancer, Patient, Research, Observation, ASA, Pharmaceutical industry

Updated C-02 survival data support the accelerated development of VB10.16, including the potential US pivotal trial C-04 in recurrent or metastatic cervical cancer, and advancing of the program into earlier stages of cervical cancer and expanding into head and neck cancer.

Key Points: 
  • Updated C-02 survival data support the accelerated development of VB10.16, including the potential US pivotal trial C-04 in recurrent or metastatic cervical cancer, and advancing of the program into earlier stages of cervical cancer and expanding into head and neck cancer.
  • Nykode will present detailed data in a future scientific publication and at a forthcoming conference.
  • The trial investigates the use of Nykode’s wholly-owned off-the-shelf therapeutic cancer vaccine candidate VB10.16 in combination with Roche’s checkpoint inhibitor atezolizumab in patients with recurrent or metastatic HPV16-positive cervical cancer.
  • Nykode wishes to thank the patients, their families and the investigators for their participation and contribution to the VB-C-02 trial.

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

Retrieved on: 
Tuesday, March 19, 2024
Motivation, Mouse, Multiple sclerosis, Capital market, ASA, Immune system, Summit, Poster, Drug development, Vaccine

Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to develop high-precision treatments for autoimmune diseases.

Key Points: 
  • Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to develop high-precision treatments for autoimmune diseases.
  • At the conference, Nykode demonstrated for the first time a significant effect in a therapeutic setting in a preclinical model for Multiple Sclerosis (MS) with its inverse vaccine platform.
  • The data also illustrate the strong contribution of the specific targeting unit and confirm that the disease protection is antigen-specific, underscoring the potential of Nykode’s technology in the field of autoimmune diseases.
  • In addition to an oral presentation, Nykode presented a poster at the Summit to elaborate on these findings.